Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms

Medicine & Life Sciences

• Receptor Protein-Tyrosine Kinases 67%
• Hematologic Neoplasms 63%
• Point Mutation 61%
• entrectinib 40%
• Mutation 35%
• ARRY-470 20%
• Drug Approval 13%
• Dimerization 11%
• Cell Surface Receptors 11%
• Neoplasm Genes 11%
• United States Food and Drug Administration 10%
• Neoplasms 10%
• High-Throughput Nucleotide Sequencing 10%
• Leukemia 8%
• Food 7%
• Lipids 6%
• Clinical Trials 6%
• Pediatrics 6%
• Cytokines 6%
• Survival 5%
• Therapeutics 1%

Chemical Compounds

• Neurotrophic 100%
• Tyrosine 57%
• Mutation 52%
• Haematological 33%
• Oncogenic 10%
• Dimerization 7%
• Lipid 5%
• Environment 4%